NEW YORK (GenomeWeb News) – Belgian molecular diagnostics firm Innogenetics said today that it will take a non-recurring charge of €7.5 million ($10.2 million) related to impairment losses on intangible assets, fixed assets, and inventories.
Innogenetics said that the losses are tied to activities “for which the business plan at this moment does not foresee significant future revenue streams.” The firm did not provide details of which activities are related to the charges.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.

A phylogenetic analysis indicates two venomous Australian spiders are more closely related than thought, the International Business Times reports.

In Science this week: CRISPR-based approach for recording cellular events, and more.

A new company says it will analyze customers' genes to find them a suitable date, though Smithsonian magazine says the science behind it might be shaky.